Literature DB >> 11320695

Lameness in feedlot cattle.

G L Stokka1, K Lechtenberg, T Edwards, S MacGregor, K Voss, D Griffin, D M Grotelueschen, R A Smith, L J Perino.   

Abstract

This article examines the various causes of lameness in feedlot cattle, with an emphasis on clinical signs, treatment, and prevention. Specific conditions are discussed, including interdigital necrobacillosis, laminitis, feedlot injuries, and feedlot lameness associated with Mycoplasma bovis. Immune management of the foot is also reviewed.

Entities:  

Mesh：

Year:  2001        PMID： 11320695     DOI： 10.1016/s0749-0720(15)30062-1

Source DB:  PubMed          Journal:  Vet Clin North Am Food Anim Pract        ISSN： 0749-0720            Impact factor:   3.357


  5 in total

1.  The lesions of toe tip necrosis in southern Alberta feedlot cattle provide insight into the pathogenesis of the disease.

Authors:  Lana A Gyan; Chad D Paetsch; Murray D Jelinski; Andrew L Allen
Journal:  Can Vet J       Date:  2015-11       Impact factor: 1.008

2.  A distinct bacterial dysbiosis associated skin inflammation in ovine footrot.

Authors:  Grazieli Maboni; Adam Blanchard; Sara Frosth; Ceri Stewart; Richard Emes; Sabine Tötemeyer
Journal:  Sci Rep       Date:  2017-03-24       Impact factor: 4.379

3.  Claw and limb disorders in 12 Norwegian beef-cow herds.

Authors:  Terje Fjeldaas; Ola Nafstad; Bente Fredriksen; Grethe Ringdal; Ase M Sogstad
Journal:  Acta Vet Scand       Date:  2007-09-24       Impact factor: 1.695

Review 4.  Perspectives on the treatment of claw lesions in cattle.

Authors:  Jan K Shearer; Paul J Plummer; Jennifer A Schleining
Journal:  Vet Med (Auckl)       Date:  2015-06-30

5.  Economic effects of policy options restricting antimicrobial use for high risk cattle placed in U.S. feedlots.

Authors:  Guillaume Lhermie; Pierre Sauvage; Loren William Tauer; Leslie Verteramo Chiu; Karun Kanyiamattam; Ahmed Ferchiou; Didier Raboisson; Harvey Morgan Scott; David R Smith; Yrjo Tapio Grohn
Journal:  PLoS One       Date:  2020-09-15       Impact factor: 3.240
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.